Forte Biosciences, Inc.
No SEC Form 4 filings for $FBRX in the last 30 days.
See all $FBRX insider activity →Forte Biosciences, Inc. (FBRX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01. Completion of Acquisition or Disposition of Assets. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions described therein and in the Offer to Purchase, dated August 6, 2026, and the related Letter of Transmittal, on August 6, 2026, Purcha
Forte Biosciences (FBRX) reports Q2 earnings with a $1.01 per share loss expected, ahead of its $2.2B acquisition by argenx at $77/share. Analysts anticipate minimal financial surprises, focusing instead on acquisition timeline updates, clinical trial progress, and cash burn. The stock trades near the deal price, with a mean target of $73.80. The tender offer expires August 26, two days post-earnings.
Forte Biosciences (FBRX) received a $77 per share cash takeover bid from argenx BV. The offer is detailed in an amended SEC filing, with updates on executive arrangements and financial projections. Guggenheim Securities provided a valuation opinion using a discount rate range of 11.75% to 14.50%.
Over the past 7 days, alphai's AI scored 2 news stories mentioning FBRX (Forte Biosciences, Inc.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent FBRX coverage spans mergers & acquisitions and earnings.
The transaction removes FBRX from public markets, likely ending any tradable equity exposure.
Forte Biosciences (FBRX) reports Q2 earnings with a $1.01 per share loss expected, ahead of its $2.2B acquisition by argenx at $77/share. Analysts anticipate minimal financial surprises, focusing instead on acquisition timeline updates, clinical trial progress, and cash burn. The stock trades near the deal price, with a mean target of $73.80. The tender offer expires August 26, two days post-earnings.
Potential acquisition at $77 per share could trigger a premium to current market price.
Tender offer can close soon, likely prompting shareholders to tender shares.
The print reinforces cash-burn risk while per-share losses improve slightly, keeping deal-execution and funding certainty central to the stock.
alphai scores every news story that mentions FBRX with an AI model for sentiment and relevance, and aggregates insider trades from Forte Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Forte Biosciences, Inc. (FBRX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01. Completion of Acquisition or Disposition of Assets. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions described therein and in the Offer to Purchase, dated August 6, 2026, and the related Letter of Transmittal, on August 6, 2026, Purcha
1 min readForte Biosciences (FBRX) reports Q2 earnings with a $1.01 per share loss expected, ahead of its $2.2B acquisition by argenx at $77/share. Analysts anticipate minimal financial surprises, focusing instead on acquisition timeline updates, clinical trial progress, and cash burn. The stock trades near the deal price, with a mean target of $73.80. The tender offer expires August 26, two days post-earnings.
2 min readForte Biosciences (FBRX) received a $77 per share cash takeover bid from argenx BV. The offer is detailed in an amended SEC filing, with updates on executive arrangements and financial projections. Guggenheim Securities provided a valuation opinion using a discount rate range of 11.75% to 14.50%.
3 min readForte Biosciences (FBRX) received a cash tender offer from argenx's subsidiary at $77.00 per share. The HSR Act waiting period expired on August 18, 2026, clearing the antitrust review. The offer remains subject to other conditions.
2 min readForte Biosciences (FBRX) reported Q2 2026 net loss of $23.33M and first-half 2026 net loss of $45.47M, both larger than prior-year periods. Basic loss per share from continuing operations narrowed to $2.18 from $2.32. The article also cites a $77/share cash tender offer tied to an argenx sale and a Simply Wall St fair value estimate of $73.8.
4 min readForte Biosciences (FBRX) is scheduled to report Q2 earnings Aug. 17, with analysts expecting a loss of $1.01 per share on zero revenue. The company is being acquired by argenx for $77 per share in cash, with the tender offer set to expire Aug. 26. Deal progress and cash/clinical updates are key for investors.
6 min readForte Biosciences (FBRX) reported Q2 2026 results on Aug. 12. It posted EPS of -$0.97, missing the -$0.90 estimate by $0.07. Revenue was $0, matching estimates. The article also cites institutional activity, including BlackRock adding shares and Point72 reducing holdings.
2 min readForte Biosciences (FBRX) reported a $45.5 million net loss for the six months ended June 30, 2026, up from $26.9 million a year earlier, citing higher FB102 clinical and manufacturing spending. Cash and investments totaled $198.5 million after a $172.5 million April 2026 equity offering. Forte agreed to be acquired by argenx via a $77-per-share cash tender offer and merger.
6 min readArgenx SE (ARGX) agreed to buy Forte Biosciences (FBRX) for about $2.2 billion in cash, offering $77 per share, a ~40% premium to Forte’s prior close. The deal includes Forte’s FB102 anti-CD122 antibody and is expected to close in Q3 2026, pending approvals. Both boards approved.
6 min readargenx (ARGX) said its subsidiary Avena Merger Sub has started a tender offer to buy all outstanding Forte Biosciences (FBRX) shares for $77.00 per share in cash, net to the seller, under a July 26, 2026 merger agreement. The offer expires Aug. 26, 2026 unless extended, and Forte’s board recommends acceptance.
5 min read
